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Background: Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm of childhood whose clinical
heterogeneity is only poorly represented by gene sequence alterations. It was previously shown that aberrant DNA
methylation of distinct target genes defines a more aggressive variant of JMML, but only few significant targets are
known so far. To get a broader picture of disturbed CpG methylation patterns in JMML, we carried out a methylation
screen of 34 candidate genes in 45 patients using quantitative mass spectrometry.
Findings: Five of 34 candidate genes analyzed showed recurrent hypermethylation in JMML. cAMP-responsive
element-binding protein-binding protein (CREBBP) was the most frequent target of epigenetic modification
(77 % of cases). However, no pathogenic mutations of CREBBP were identified in a genetic analysis of 64
patients. CREBBP hypermethylation correlated with clinical parameters known to predict poor outcome.
Conclusions: This study supports the relevance of epigenetic aberrations in JMML pathophysiology. Our data
confirm that DNA hypermethylation in JMML is highly target-specific and associated with higher-risk features.
These findings encourage the development of prognostic markers based on epigenetic alterations, which will
be helpful in the difficult clinical management of this heterogeneous disease.
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Risk assessment in juvenile myelomonocytic leukemia
(JMML) is important for clinical decision-making as this
aggressive myeloproliferative neoplasm is generally unre-
sponsive to conventional chemotherapy and most (but
not all) patients need early allotransplantation [1, 2].
Several clinical parameters have been well-established to
predict poor outcome [2], but the picture is less clear at
the molecular level. Specifically, if and how the set of
genetic mutations in leukemic cells contributes to* Correspondence: silvia.fluhr@uniklinik-freiburg.de
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Recent research on epigenetic dysregulation in JMML
has provided a growing body of evidence that high-risk
cases of JMML are characterized by specific CpG island
hypermethylation which integrates the clinical and genetic
risk factors identified so far [5–7]. To provide a broader
picture of epimutations in JMML, we carried out a DNA
methylation analysis of 34 candidate genes in leukemic
cells from 45 children with JMML.Aberrant methylation of CREBBP, MPO, SLC12A8,
HIC1, and TCF4 in JMML
We assessed the CpG island methylation of 34 candidate
genes (Fig. 1a) in granulocyte DNA from 45 children with
JMML and 11 healthy adult individuals using quantitative
high-resolution mass spectrometry. Selection of twenty-
five candidate genes followed a methylation panel in acutes distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Candidate genes selected because of aberrant methylation in acute myeloid leukemia (Ref. 8)
CDCA5 CREBBP CXCR4 DAPK1 EPOR ESR1 ETV6 FAM49B FOS HIC1 HIC2
KMT2C 
(MLL3) MPO
NFAT5 NUP133 PBX1 PRG2 RB1 RUNX1 SLC12A8 SLC25A13 TAL1 TCF4 TLX3 ZNF25
Candidate genes in a commonly deleted region on chromosome 7q22 (Ref. 9)
ARMC10
KMT2E 
(MLL5) LHFPL3 NAPEPLD PMPCB PUS7 RELN RINT1 SLC26A5
Fig. 1 DNA methylation analysis of 34 genes in 45 children with JMML and 11 healthy controls. a Candidate genes for analysis of CpG island
methylation in JMML. b CREBBP, MPO, and SLC12A8 were recurrently hypermethylated in JMML. CpG methylation of the indicated target regions
was determined in granulocyte DNA from children with JMML and healthy control subjects using quantitative mass spectrometry. The average
level of methylation across all CpG units is shown for each sample. A JMML sample was categorized as hypermethylated if the methylation level
exceeded three standard deviations above the mean observed in healthy controls. The upper limit of normal methylation is illustrated by a dotted line.
The significance of differences was calculated using the Mann-Whitney test and is indicated as follows: *p≤ 0.0014 (Bonferroni threshold for significance
level p ≤ 0.05 after correction for 36 tests, i.e., 34 genes plus HIC1 CpG 3359 and TCF4 CpG 1515); ns, p > 0.0014. c The HIC1 and TCF4 genes
had normal methylation in JMML when averaging all CpG units in the region of analysis, but each region contained a single CpG unit with
significant hypermethylation in JMML
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that monosomy 7 is the most frequent cytogenetic abnor-
mality observed in JMML cells [2], and reasoning that a
two-hit mechanism of tumor suppressor inactivation
might involve hypermethylation of the second allele after
deletion of one allele, we selected an additional nine genes
because of their location in a ~2.5 mega base pair region
on chromosome segment 7q22 which is commonly de-
leted in myeloid malignancies [9]. In the cohort used here,
monosomy 7 was present in 11/45 cases (24 %). Detailed
information on the DNA regions interrogated by the mass
spectrometry assays is given in Additional file 1: Table S1.
We defined a gene as hypermethylated in a JMML
sample if the average CpG methylation in the region of
analysis exceeded three standard deviations above themean observed in granulocytes of 11 healthy control
subjects. Using this definition, 34 of 44 JMML cases
(77 %) showed hypermethylation of the cAMP-responsive
element-binding protein-binding protein (CREBBP) gene
(the assay was uninformative in one case), 20 of 45 (44 %)
were hypermethylated in the MPO gene, and 19 of 45
(42 %) carried a hypermethylated SLC12A8 gene (Fig. 1b).
Most CpG units analyzed in the HIC1 and TCF4 genes
had normal methylation in JMML, but each region con-
tained a single CpG unit near its border with significant
hypermethylation in JMML (Fig. 1c). This observation
may hint at aberrant methylation in neighboring regions
not covered by the assay. A group-wise comparison of
methylation levels using Mann-Whitney test with
Bonferroni correction showed for each gene a highly
Fluhr et al. Clinical Epigenetics  (2016) 8:50 Page 3 of 5significant difference between the “hypermethylated JMML”
group and healthy controls but no difference between “nor-
mal methylation JMML” and controls (Fig. 1b, c). The
DNA methylation level of the remaining 29 genes was simi-
lar between JMML samples and healthy granulocytes or the
difference was so small that no biological significance
would be expected (Additional file 1: Table S1).
The analysis demonstrates that CpG hypermethylation in
JMML is highly locus-specific. Although a significant pro-
portion of JMML cases are characterized by aberrant DNA
methylation, the hypermethylation events are confined to a
limited array of genetic regions. This observation fits well
with three previous studies where 11 of 15 candidate re-
gions did not show any aberrant methylation in 127 cases
analyzed [5], or where hypermethylation was restricted to
only one of two CpG islands of the RASA4 locus [6] or one
of three CpG islands of the AKAP12 locus [10]. Contrary
to the two-hit hypothesis formulated above, none of the
nine 7q22 genes exhibited frequent hypermethylation in



















































































Fig. 2 Epigenetic dysregulation of CREBBP in JMML and association with cl
methylation profile of a CpG-rich 437-base pair region upstream of the CRE
CpG units under physiological conditions and frequent hypermethylation i
units in granulocyte DNA from 11 healthy control subjects (open boxes) and 4
the median, and the bottom and top of the box represent the first and t
and maximum values. The significance of differences was calculated usin
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. b Methylation of CREBBP CpG site
dramatically in most JMML cases. The average level of methylation across
categorized as hypermethylated if the methylation level exceeded three
The upper limit of normal methylation is illustrated by a dotted line. c In s
binding motifs for GATA1/2 and GTF3A at CpG sites #8 to #10. d CREBBP
and elevated fetal hemoglobin (HbF) at diagnosis, two established predicHigh-resolution DNA methylation analysis of the
CREBBP CpG island in JMML
The CREBBP gene was hypermethylated in 77 % of
JMML cases. CREBBP is a histone acetyltransferase
and functions as transcriptional co-activator of a large
number of regulatory proteins [11]. Mice with a null
mutation in one CREBBP allele develop a myelodysplastic/
myeloproliferative neoplasm [12]. Decreased expression of
CREBBP facilitates Ras-induced transformation [13]. The
CREBBP methylation assay used here covered 13 CpG
units in a 437-base pair region located 1.5 kilobases up-
stream of the transcription start site. Most CREBBP CpG
units were characterized by remarkable baseline methy-
lation in healthy controls which increased to even higher
levels in JMML (Fig. 2a). However, three CREBBP CpG
units (containing CpG sites #8, #9, #10, and #22) were
virtually unmethylated in healthy granulocytes. Of these,
CpG sites #8 to #10 acquired particularly high hyperme-
thylation in JMML (Fig. 2b), raising the possibility of




































































































inical parameters indicating poor outcome. a The high-resolution DNA
BBP transcription start site revealed high methylation variation between
n JMML. The box plots depict the methylation level of 13 CREBBP CpG
4 patients with JMML (filled boxes). The band inside the box represents
hird quartiles. The ends of the whiskers correspond to the minimum
g the Mann-Whitney test and is indicated as follows: ns, p > 0.05;
s #8 to #10 was low under physiological conditions but increased
CpG units #8–#10 is shown for each sample. A JMML sample was
standard deviations above the mean observed in healthy controls.
ilico prediction of transcription factor binding sites (TFBIND) revealed
CpG #8–#10 methylation was associated with older age (≥2 years)
tors of poor outcome. ***p ≤ 0.001 (Mann-Whitney test)
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interfere with binding motifs for the transcription fac-
tors GATA1/2 and GTF3A (Fig. 2c).
Somatic CREBBP mutations are uncommon in
JMML
We next studied if the CREBBP locus was not only subject
to epigenetic modification in JMML, but also to genetic
mutation. We analyzed leukemic granulocyte DNA from
64 children with JMML (17 of which overlapped with the
44-patient series used for epigenetic analysis) for CREBBP
exon sequence variants using the Agilent SureSelect v4.0
capture technique and deep-sequencing, resulting in an
average CREBBP exon depth of 82 reads. Eighty percent
of CREBBP exons were covered by at least 50 reads. No
insertions or deletions in the CREBBP gene were found
in any JMML sample. After removing common non-
pathogenic single-nucleotide polymorphisms documented
in public databases such as dbSNP, we identified 10 non-
synonymous sequence variants in 11 cases of JMML
(Additional file 1: Table S2). All except one (c.A493G)
were listed in at least one of four exome variation re-
sources (Exome Variant Server, ExAC browser, 1000
Genomes, dbSNP) with minor allele frequencies of less
than 0.1 %. Three variants (c.A5933G, c.A2728G,
c.G2941A) corresponded to alterations associated with
Rubinstein-Taybi syndrome [15, 16]. However, indica-
tive clinical features (facial dysmorphism, thumb or toe
malformation, intellectual disability) were documented
in none of the 11 children. Importantly, we did not de-
tect any of the CREBBP histone acetyltransferase do-
main mutations described as pathogenic somatic events
in lymphoblastic leukemia or lymphoma [17–20]. DNA
from paired non-hematopoietic tissue was available in 5
of 11 JMML cases with non-synonymous CREBBP se-
quence variants, enabling us to test the germline status.
In all cases, the variants were present in non-leukemic
tissue. The pathogenic significance of these germline
CREBBP variants in JMML patients without syndromic
features remains unclear. Taken together, the data indi-
cate that the coding sequence of CREBBP is not a relevant
target of somatic alteration in JMML, in agreement with
the absence of CREBBPmutations from myeloproliferative
neoplasms in adults [21].
CREBBP methylation is associated with established
hematologic and clinical parameters indicating an
aggressive JMML phenotype
It was repeatedly shown that DNA hypermethylation at
specific target genes in JMML is associated with clinical
parameters indicating poor prognosis [5–7, 10]. To test
if this relationship was also true for CREBBP methyla-
tion, we focused on CpG sites #8 to #10 because these
sites were unmethylated in healthy individuals but hadhigh methylation variation in JMML. The level of methy-
lation at these sites was significantly associated with older
age and elevated fetal hemoglobin at diagnosis (Fig. 2d
and Additional file 1: Table S3), two main predictors of re-
duced survival [1, 2]. In addition, methylation at CpG sites
#8 to #10 was associated with the category of Ras pathway
mutation (Additional file 1: Table S3), being considerably
higher in JMML cases with PTPN11 mutation or neuro-
fibromatosis type 1 (NF1) than in JMML with KRAS,
NRAS, or CBL mutation. The relevance of the mutation
category to disease course and outcome of JMML remains
controversial [2–4, 22], but higher CREBBP methylation
in JMML with PTPN11 mutation or NF1 is consistent
with the prevailing opinion that these subgroups are
more aggressive. Variable correlation with age, high
fetal hemoglobin, mutation, or karyotype but no other
parameters was also found for MPO, SLC12A8, and
HIC1 CpG 3359. The small group size and heterogeneous
treatment precluded meaningful outcome analyses. How-
ever, we noted that five events of death occurred in the
CREBBP hypermethylation group (5/34 patients, 15 %)
compared to no such event in the group with normal
CREBBP methylation (0/10 patients); the median follow-
up time was 6.0 years for all 44 patients. In summary, the
data strengthen the concept that higher-risk cases of
JMML carry a distinct DNA methylation phenotype. Fu-
ture studies are needed to elucidate the functional role of
coordinated DNA hypermethylation at specific loci in the
JMML-initiating cell.Study design
Patient samples
We used clinical material from German JMML patients
registered in the European Working Group of MDS in
Childhood (EWOG-MDS) studies “98” and “2006” after
obtaining informed consent and ethics approval (University
of Freiburg, reference number EK247/05). Patients with
Noonan syndrome (PTPN11 or KRAS germline muta-
tion) were excluded. Clinical characteristics are given in
Additional file 1: Table S3.High-resolution quantitative DNA methylation
analysis
Leukemic granulocytes from 45 patients (bone marrow,
N = 36; peripheral blood, N = 9) were enriched by Ficoll
centrifugation (Biochrom). Genomic DNA was isolated
using the Gentra Puregene kit (Qiagen) and bisulfite con-
verted using the EZ DNA methylation kit (Zymo Research).
The MassARRAY EpiTYPER assay (Agena Bioscience) was
used to assess CpG island methylation at 34 target regions
(Fig. 1a and Additional file 1: Table S1). Primer sequences
are listed in Additional file 1: Table S4.
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Library construction and exon region capture of frag-
mented genomic DNA isolated from leukemic granulo-
cytes of 64 patients were done using TruSeq (Illumina)
and SureSelect v4.0 (Agilent). 100-base pair paired-end
sequencing was performed on HiSeq2000 instruments
(Illumina). The reads were aligned to the hg19 reference
genome. CREBBP single-nucleotide polymorphisms and
indels were identified according to standard recommen-
dations (Genome Analysis Toolkit, Broad Institute).
Additional file
Additional file 1: This file contains additional details on methods and
Tables S1–S4. (PDF 218 kb)
Abbreviations
JMML: juvenile myelomonocytic leukemia; CREBBP: cAMP-responsive
element-binding protein-binding protein; NF1: neurofibromatosis type 1.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
SF, TW, DBL, and OM carried out the DNA methylation analysis and analyzed
the data. MB, HB, and AS analyzed the deep-sequencing data. PN performed
the statistical analysis. CMN provided the patient material and clinical data
and revised the manuscript. CFK and CP analyzed the data and revised the
manuscript. SF and CF devised the research, analyzed the data, and wrote
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are grateful to A. Meier for technical assistance. Grant support: German
Research Foundation (CRC 992-C05 to CF, SPP1463 FL345/4-2 to SF and CF,
CRC 850 to AS).
Author details
1Division of Pediatric Hematology and Oncology, Department of Pediatrics
and Adolescent Medicine, University Medical Center, Mathildenstrasse 1,
79106 Freiburg, Germany. 2Hermann Staudinger Graduate School, University
of Freiburg, Freiburg, Germany. 3Institute of Molecular Medicine and Cell
Research, University of Freiburg, Freiburg, Germany. 4German Cancer
Research Center (DKFZ), Heidelberg, Germany. 5German Cancer Consortium
(DKTK), Heidelberg, Germany. 6Division of Epigenomics and Cancer Risk
Factors, German Cancer Research Center, Heidelberg, Germany.
Received: 16 February 2016 Accepted: 27 April 2016
References
1. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al.
Hematopoietic stem cell transplantation (HSCT) in children with juvenile
myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.
Blood. 2005;105(1):410–9.
2. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia.
Blood. 2015;125(7):1083–90.
3. Flotho C, Kratz CP, Bergsträsser E, Hasle H, Starý J, Trebo M, et al. Genotype-
phenotype correlation in cases of juvenile myelomonocytic leukemia with
clonal RAS mutations. Blood. 2008;111(2):966–7.
4. Niemeyer CM, Strahm B, Dworzak M, de Moerloose B, Hasle H, Stary J, et al.
JMML revisited: role and outcome of hematopoietic stem cell transplantation
in subtypes of juvenile myelomonocytic leukemia. Blood. 2012;120(21):955.
5. Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, et al.
Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia
(JMML) with poor outcome. Blood. 2011;117(18):4871–80.6. Poetsch AR, Lipka DB, Witte T, Claus R, Nöllke P, Zucknick M, et al. RASA4
undergoes DNA hypermethylation in resistant juvenile myelomonocytic
leukemia. Epigenetics. 2014;9(9):1252–60.
7. Sakaguchi H, Muramatsu H, Okuno Y, Makishima H, Xu Y, Furukawa-Hibi Y,
et al. Aberrant DNA methylation is associated with a poor outcome in
juvenile myelomonocytic leukemia. PLoS One. 2015;10(12):e0145394.
8. Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, et al.
Decitabine induces very early in vivo DNA methylation changes in blasts
from patients with acute myeloid leukemia. Leuk Res. 2013;37(2):190–6.
9. Kratz CP, Emerling BM, Donovan S, Laig-Webster M, Taylor BR, Thompson P,
et al. Candidate gene isolation and comparative analysis of a commonly
deleted segment of 7q22 implicated in myeloid malignancies. Genomics.
2001;77(3):171–80.
10. Wilhelm T, Lipka DB, Witte T, Wierzbinska JA, Fluhr S, Helf M, et al. Epigenetic
silencing of AKAP12 in juvenile myelomonocytic leukemia. Epigenetics.
2016; in press.
11. Kung AL, Rebel VI, Bronson RT, Ch’ng LE, Sieff CA, Livingston DM, et al.
Gene dose-dependent control of hematopoiesis and hematologic tumor
suppression by CBP. Genes Dev. 2000;14(3):272–7.
12. Zimmer SN, Lemieux ME, Karia BP, Day C, Zhou T, Zhou Q, et al. Mice
heterozygous for CREB binding protein are hypersensitive to gamma-radiation
and invariably develop myelodysplastic/myeloproliferative neoplasm. Exp
Hematol. 2012;40(4):295–306.
13. Sanchez-Molina S, Estaras C, Oliva JL, Akizu N, Asensio-Juan E, Rojas JM, et al.
Regulation of CBP and Tip60 coordinates histone acetylation at local
and global levels during Ras-induced transformation. Carcinogenesis.
2014;35(10):2194–202.
14. Tsunoda T, Takagi T. Estimating transcription factor bindability on DNA.
Bioinformatics. 1999;15(7–8):622–30.
15. Coupry I, Roudaut C, Stef M, Delrue MA, Marche M, Burgelin I, et al.
Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi
syndrome. J Med Genet. 2002;39(6):415–21.
16. Bartsch O, Kress W, Kempf O, Lechno S, Haaf T, Zechner U. Inheritance and
variable expression in Rubinstein-Taybi syndrome. Am J Med Genet A.
2010;152A(9):2254–61.
17. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA,
et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature.
2011;471(7337):235–9.
18. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V,
et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Nature. 2011;471(7337):189–95.
19. Huether R, Dong L, Chen X, Wu G, Parker M, Wei L, et al. The landscape of
somatic mutations in epigenetic regulators across 1,000 paediatric cancer
genomes. Nat Commun. 2014;5:3630.
20. Nielsen JS, Sedgwick C, Shahid A, Zong Z, Brumme ZL, Yu S, et al. Toward
personalized lymphoma immunotherapy: identification of common driver
mutations recognized by patient CD8+ T cells. Clin Cancer Res. 2015.
[Epub ahead of print]
21. Andersen CL, Hasselbalch H, Gronbaek K. Lack of somatic mutations in
the catalytic domains of CREBBP and EP300 genes implies a role for
histone deacetylase inhibition in myeloproliferative neoplasms. Leuk Res.
2012;36(4):485–7.
22. Yoshida N, Yagasaki H, Xu Y, Matsuda K, Yoshimi A, Takahashi Y, et al.
Correlation of clinical features with the mutational status of GM-CSF
signaling pathway-related genes in juvenile myelomonocytic leukemia.
Pediatr Res. 2009;65(3):334–40.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
